SecBot SecBot
6-K ·Filed Jun 10, 2026

PYPD

PolyPid Ltd.
NEUTRAL
Impact 3/10
Horizonweeks Processed4mo ago SEC0001213900-26-067311
Notable filing: 6-K
Actionable Insight • Neutral

This filing contains no new operational or financial data — it is a routine proxy solicitation for standard governance items. Traders should monitor the July 15, 2026 meeting outcome for any unexpected voting results but no near-term price catalyst is present. Watch for future 6-K filings for any material pipeline or clinical trial updates.

DirectionNeutral
Confidencehigh
Horizonweeks
Final — all horizons settled through T+60d
PYPD ▲ +16.63% at T+60d
NEUTRAL call +16.63% · α vs SPY +12.81% · entry $4.57 → $5.33
Entry = T+0 close
Jun 10, 2026
via day close
T+1d
+1.09%
call +1.09% · α +0.55%
$4.62
settled 5mo ago
T+5d
-0.22%
call -0.22% · α -0.65%
$4.56
settled 4mo ago
T+20d
+18.60%
call +18.60% · α +16.71%
$5.42
settled 4mo ago
T+60d
+16.63%
call +16.63% · α +12.81%
$5.33
settled 8w ago

Price Chart

Loading chart...

Executive Summary

PolyPid filed a 6-K furnishing proxy materials for its Annual and Extraordinary General Meeting on July 15, 2026. The meeting includes routine items (re-election of auditor and eight directors, approval of director compensation, discussion of FY2025 financials) and two compensation-related Special Majority votes: amending non-executive director option terms (9,132 options per director at a $4.46 exercise price) and granting 149,000 CEO options to Dikla Czaczkes Akselbrad at $4.46 per share. No material financial data, operational updates, or strategic catalysts are disclosed — this is a routine governance filing with no stock-moving information.

Key Facts

  • Annual and Extraordinary General Meeting scheduled for July 15, 2026, at 2:00 p.m. Israel time
  • Record date for voting is June 15, 2026
  • Proposal 1: Re-elect EY (Kost Forer Gabbay & Kasierer) as independent auditor
  • Proposal 2: Re-elect eight directors (Dikla Czaczkes Akselbrad, Brooke Story, Yechezkel Barenholz, Joseph BenAmram, Nir Dror, Yitzchak Jacobovitz, Itzhak Krinsky, Robert B. Stein) and approve their compensation
  • Proposal 3: Amend non-executive director option terms — 9,132 options per director at $4.46 exercise price (30-day VWAP before May 11, 2026)
  • Proposal 4: Grant 149,000 CEO options to Dikla Czaczkes Akselbrad at $4.46 per share, vesting quarterly over 4 years
  • Proposal 5: Discuss FY2025 financial statements (no vote required)
  • Chairman Brooke Story receives $75,000 fixed annual fee; non-Israeli directors get $20,000 annual fee; Israeli directors get NIS 37,000 (~$13,100) annual fee
  • Mr. Jacobovitz waives director compensation
  • This 6-K is incorporated by reference into five existing F-3 shelf registration statements and five S-8 registration statements

Financial Impact

No revenue, earnings, or cash flow figures disclosed. The option grants represent annual director compensation of $40,000 per non-executive director and CEO options for 149,000 shares at $4.46. At $87M market cap, potential full dilution from CEO options is ~$0.67M (under 1% of market cap) at the exercise price — immaterial.

dilution

Risk Factors

  • Proxy vote failure on Special Majority items (Proposals 3 and 4) could cause minor governance friction but no material business impact
  • Option grants add minor dilution (~149k CEO shares + ~54.8k non-executive director shares = ~203.8k total potential shares, likely under 3% of outstanding)

Market Snapshot

Exchange
Nasdaq
Sector
Surgical & Medical Instruments & Apparatus
Analyst Consensus
90% bullish (10 analysts)

Investment Themes

Healthcare & Medical Devices

Documents Analyzed

This report is based on 7 SEC documents filed with EDGAR.

DocumentAccession Number
6-K Filing (Primary)0001213900-26-067311
Document: ea029409201ex99-3.htm0001213900-26-067311
Document: ea0294092-6k_polypid.htm0001213900-26-067311
Document: ea029409201ex99-1.htm0001213900-26-067311
Document: 0001213900-26-067311-index-headers.html0001213900-26-067311
Document: 0001213900-26-067311-index.html0001213900-26-067311
Document: 0001213900-26-067311.txt0001213900-26-067311
21 reports for PYPD
Performance horizon
100% Hit rate @ T+60 9 of 9 directional calls Went positive at some point 12 of 15 best @ T+60▲ +29.14%Jul 21, 2026
Filters
Rows
Reports for PYPD — sortable, filterable
TypeNow
Oct 15, 2026
11d ago
Press Release
NEUTRAL ★ 3/10
$4.90awaiting T+60—$5.29 (+7.96%)
Oct 1, 2026
25d ago
6-K
BULLISH ★ 7/10
$5.37awaiting T+60—$5.29 (−1.49%)
Oct 1, 2026
25d ago
Press Release
BULLISH ★ 7/10
$5.37awaiting T+60—$5.29 (−1.49%)
Oct 1, 2026
25d ago
6-K
BULLISH ★ 6/10
$5.37awaiting T+60—$5.29 (−1.49%)
Oct 1, 2026
25d ago
Press Release
MIXED ★ 5/10
$5.37awaiting T+60—$5.29 (−1.49%)
Aug 12, 2026
10w ago
6-K
BULLISH ★ 7/10
$4.78awaiting T+60—$5.29 (+10.67%)
Aug 12, 2026
10w ago
6-K
BULLISH ★ 8/10
$4.84awaiting T+60—$5.29 (+9.30%)
Aug 12, 2026
10w ago
Press Release
BULLISH ★ 7/10
$4.84awaiting T+60—$5.29 (+9.30%)
Jul 29, 2026
12w ago
6-K
BULLISH ★ 7/10
$4.08 $5.13▲ +25.74%▲ +21.01%$5.29 (+29.66%)
Jul 21, 2026
13w ago
6-K
BULLISH ★ 7/10
$3.74 $4.83▲ +29.14%▲ +26.30%$5.29 (+41.44%)
Showing 10 of 21

US Market Status

Market Closed — Opens in 7h 28m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Jun 10, 2026